Efficiency and safety of Tripterygium Wilfordii Hook F for IgA nephropathy: an update systematic review and meta-analysis  

作　　者：Zi-Yi He Hui-Chuan Tian Yan Zhao Rui-Yu Mou Hong-Wei Yuan 

机构地区：[1]Department of Cardiology,The Second Affiliated Hospital of Tianjin University of Chinese Medicine,Tianjin 300150,China [2]Department of Oncology,The First Affiliated Hospital of Tianjin University of Chinese Medicine,Tianjin 300110,China [3]Department of Oncology,National Clinical Research Center of Chinese Acupuncture and Moxibustion,Tianjin 301617,China [4]Department of Chinese Medicine,Macao University of Science and Technology,Macao 999078,China

出　　处：《Pharmacology Discovery》2024年第2期24-31,共8页

基　　金：supported by the Foundation.The authors are grateful to Dr.Jia Yingjie for his help with the preparation of the ideas in this paper.

摘　　要：Background:Immunoglobulin A Nephropathy(IgAN)currently stands as the most prevalent primary chronic glomerular disease worldwide.The latest guidelines recommend the application of renin-angiotensin system inhibitors(RASi)in conjunction with corticosteroids for the treatment of IgAN patients exhibiting persistent proteinuria of≥1 g/d.However,numerous randomized controlled trials(RCTs)have revealed a heightened risk of adverse events associated with corticosteroid treatment.Multi-glycoside of Tripterygium wilfordii Hook.f.(GTW),a traditional Chinese medicine(TCM),has been employed in the treatment of Chronic Kidney Disease(CKD)for an extensive period.Recent years have witnessed an increasing number of RCTs providing evidence supporting the effectiveness of GTW therapy in IgAN.Despite this,there remains a paucity of systematic reviews on the application of GTW therapy for IgAN.Consequently,this study undertakes a systematic review to assess the clinical efficacy and safety of GTW therapy,aiming to elucidate the role of GTW therapy in the treatment of IgAN.Methods:To collect relative information of randomized controlled trials(RCTs)of GTW in the treatment of IgAN,we searched for theses and dissertations publicized before April 10,2023,in PubMed,Embase,the Cochrane Library,China National Knowledge Infrastructure(CNKI),Wanfang Data knowledge service platform(Wanfang Data),Chinese Scientific Journal Database(VIP),and Clinical Trial.The language limitation is English and Chinese.Independently,two reviewers performed literature screening,data extraction,and quality evaluation,and the meta-analysis was carried out with RevMan 5.4 and StataSE 15.0 software.Results:21 RCTs involving 1,405 Chinese patients were included.Compared to ACEI/ARB alone or in combination,GTW with RASi or alone reduced 24 h-Upro,ALB,Scr,GFR,BUN,CD4+,VEGF,ET-1,and improved clinical efficacy.However,no associations were found for TC,Ccr,and adverse events due to limited literature.Conclusion:This study highlights that Multi-glycoside of Tripterygium

关 键 词：TRIPTERYGIUM IgA nephropathy systematic review META-ANALYSIS 

分 类 号：R69[医药卫生—泌尿科学]